



an Open Access Journal by MDPI

Role of Natural Product in Cardiovascular Disease

Guest Editors:

Dr. Jian Li

Center for Molecular and
Translational Medicine, Georgia
State University, 157 Decatur
Street, SE, Atlanta, GA 30303, USA

Prof. Dr. Qilong Wang

Institute of Traditional Chinese
Medicine, Tianjin University of
Traditional Chinese Medicine,
Tianjin 301617, China

Dr. Jingrui Chen

Department of Pharmaceutical
Sciences, Washington State
University, 412 E. Spokane Falls
Blvd., Spokane, WA 99202-2131,
USA

Message from the Guest Editors

Cardiovascular disease (CVD), generally referring to a group of disorders of the heart and vessels as well as their associated adverse conditions, has been the leading cause of morbidity and mortality worldwide. The majority of CVD is caused by physiological or metabolic risk factors that can be controlled, modified or treated, such as hyperlipidemia, blood viscosity, atherosclerosis, hypertension, obesity and diabetes. Currently, the common therapeutical medication strategies of CVD have largely depended on lipid-lowering statins, blood thinners, and beta blockers. However, some patients do not achieve ideal effects from these traditional therapeutics. Therefore, there is still an unmet medical need to seek new therapeutic modalities for CVD treatment.

Deadline for manuscript
submissions:

closed (31 December 2023)



mdpi.com/si/160234

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI